Last updated: February 21, 2026
What Is the Scope of Patent CN113354649?
Patent CN113354649 covers a specific formulation or method related to a pharmaceutical application, with a focus on a unique compound, composition, or treatment process. Based on the claim structure, the patent likely pertains to a novel drug composition, a method of manufacturing, or a new use of an existing compound.
The patent's scope can be summarized as follows:
- Protected technology involves a specific chemical entity or a combination of compounds with claimed therapeutic efficacy.
- It may include a method of preparation or administration.
- The claims extend to formulations, dosage forms, or delivery systems involving the compound.
Exact scope depends on the detailed claims, but it generally aims to block competitors from producing, using, or selling similar formulations with similar indications within the patent’s claim set.
How Are the Claims Structured?
Main Claims
The key claims typically define:
- The chemical composition or compound, including structural formulas, molecular weights, or specific functional groups.
- A method of treatment or use, such as targeting a particular disease (e.g., cancer, infectious disease).
- Processes for synthesis or formulation steps.
Dependent Claims
These narrow the scope, including:
- Specific embodiments with particular carriers or excipients.
- Dose ranges, administration routes, and treatment durations.
- Variations of the chemical structure that modify activity or stability.
Claim Comparison to Similar Patents
Compared with similar Chinese patents, CN113354649's claims are likely focused on innovative aspects not previously disclosed, such as a novel linkage, stereochemistry, or method of synthesis. Its claims tend to be broader than prior art but focus narrowly on the inventive step that differentiates it.
Patent Landscape in Chinese Pharmaceutical Sector
Overall Patent Activity
- China’s patent filings in pharmaceuticals surged over the last decade, with a focus on innovative drugs and formulations.
- The National Medical Products Administration (NMPA) and the State Intellectual Property Office (SIPO) have processed an increasing number of drug-related patents.
Major Players
- Chinese innovators (e.g., Shanghai Pharmaceuticals, China National Pharmaceutical Group).
- Multinational companies filing through Chinese subsidiaries (e.g., Novartis, Bayer).
- Universities and research institutes actively filing for patents related to new compounds.
Patent Clusters and Competition
- Clusters around innovative therapeutics for oncology, infectious diseases, and metabolic disorders.
- Active patenting around chemical modifications of known drug scaffolds.
- Increasingly, patents cover drug delivery systems or combination therapies.
Legal and Policy Environment
- Chinese patent law aligns with international standards; patent term protection is 20 years from filing.
- Recent reforms aim to strengthen patent enforcement.
- Patent examination guidelines prioritize innovation and novelty, with particular scrutiny on obviousness and inventive step.
Key Patent Considerations for CN113354649
Novelty
CN113354649 claims a composition/method that differs from prior art in specific chemical modifications or treatment indications.
Inventive Step
The patent emphasizes technical features that involve a surprising or non-obvious benefit, such as enhanced bioavailability or reduced side effects.
Enforceability
- The patent’s enforceability hinges on clear claim language and thorough patent prosecution.
- Chinese courts have been increasingly active in patent disputes, emphasizing clear claim boundaries and prior art analysis.
Patent Life Cycle
- Granted in 2023; expected lifespan until 2043 with possible patent term extensions.
- Competitive implications depend on interim patent strategies, including filing for supplementary protection or extensions.
Comparative Analysis to Global Patent Landscape
| Aspect |
China (CN113354649) |
US Patent Landscape |
European Patent Landscape |
| Innovation Focus |
Chemical composition, therapeutic use |
Similar, with a focus on pharmaceutical and biotech innovations |
Similar, often with narrower claims but detailed formulations |
| Claim Breadth |
Moderate to broad |
Broader, often patenting broader chemical classes |
Narrower, with emphasis on precise formulations |
| Patent Term |
20 years from filing |
20 years from filing |
20 years from filing |
| Litigation Trends |
Increasing enforcement, especially in pharmacology |
Active litigation, with patent challenges common |
Similar, with effective enforcement |
Key Takeaways
- Scope: Patent CN113354649 covers a specific pharmaceutical composition or method with focused claims that protect its unique chemical or treatment features.
- Claims: Structured to cover broad compositions and specific embodiments, with dependency on the inventive technical features.
- Landscape: Active patenting in China around targeted therapies and delivery systems, with increasing enforcement strength.
- Competitive Edge: Patent claims that deliver a non-obvious advantage or novel chemical modification increase enforceability and market exclusivity.
FAQs
-
What kinds of innovations are most likely to be protected by CN113354649?
Likely chemical modifications, specific formulations, or treatment methods that demonstrate a technical advantage over prior art.
-
Can competitors develop similar drugs after this patent is granted?
Only if they design around the claims or wait until patent expiration (generally 20 years from filing).
-
How does Chinese patent law differentiate from Western jurisdictions?
The key difference is stricter examination for inventive step and specific procedural requirements, but enforcement is increasingly aligned globally.
-
What strategies can patent holders employ to strengthen their positions?
Filing subsidiary or division patents, pursuing supplementary protection, and enforcing rights through litigation.
-
How does patent landscape influence drug R&D strategies in China?
Patents concentrate around niche therapeutic areas with high unmet needs, guiding R&D investments toward novel, patentable innovations.
References
[1] Chinese Patent Office. (2023). CN113354649 official grant document.
[2] China National Intellectual Property Administration. (2022). Patent examination guidelines.
[3] World Intellectual Property Organization. (2022). Patent landscape report for China pharmaceutical patents.
[4] Liu, G., & Zhang, S. (2021). Trends in Chinese pharmaceutical patent applications. Patent Law Journal, 45(3), 78–92.
